Spero Therapeutics (NASDAQ:SPRO) Insider Esther Rajavelu Sells 40,270 Shares

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) insider Esther Rajavelu sold 40,270 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $2.37, for a total value of $95,439.90. Following the completion of the sale, the insider directly owned 869,450 shares of the company's stock, valued at approximately $2,060,596.50. This represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Spero Therapeutics Trading Up 1.5%

NASDAQ:SPRO traded up $0.04 on Wednesday, hitting $2.66. 751,997 shares of the company's stock traded hands, compared to its average volume of 1,163,906. The company has a market cap of $149.70 million, a PE ratio of -2.71 and a beta of 1.55. Spero Therapeutics, Inc. has a 1 year low of $0.51 and a 1 year high of $3.22. The firm has a 50-day moving average price of $2.18 and a 200-day moving average price of $2.09.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.35. Spero Therapeutics had a negative net margin of 110.35% and a negative return on equity of 120.27%. The business had revenue of $14.19 million during the quarter, compared to analyst estimates of $11.00 million. On average, research analysts forecast that Spero Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Spero Therapeutics in a research report on Wednesday, October 8th. Zacks Research downgraded shares of Spero Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 13th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $5.00.

Get Our Latest Stock Analysis on SPRO

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Anson Funds Management LP lifted its stake in shares of Spero Therapeutics by 98.9% in the 1st quarter. Anson Funds Management LP now owns 7,638,818 shares of the company's stock valued at $5,500,000 after purchasing an additional 3,798,932 shares during the last quarter. Stonepine Capital Management LLC acquired a new position in Spero Therapeutics during the second quarter worth $455,000. GSA Capital Partners LLP bought a new position in Spero Therapeutics during the third quarter valued at about $201,000. Vanguard Group Inc. raised its holdings in Spero Therapeutics by 2.0% during the third quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company's stock valued at $3,741,000 after buying an additional 39,474 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Spero Therapeutics in the third quarter worth about $70,000. Institutional investors own 25.60% of the company's stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.

Read More

• Five stocks we like better than Spero Therapeutics
• How Technical Indicators Can Help You Find Oversold Stocks
• Rare Earth Stocks: The Truce That Isn't a Truce
• Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
• Carving Up Profits: 3 Food Stocks on the Thanksgiving Table
• Special Purpose Acquisition Company (SPAC) What You Need to Know
• C3.ai's Reset: Why New Leadership Could Spark a Turnaround

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Spero Therapeutics Right Now?

Before you consider Spero Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spero Therapeutics wasn't on the list.

While Spero Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here